Thermo Fisher Expands Gibco™ Efficient-Pro Portfolio With New Insulin-Enhanced Medium

Thermo Fisher Scientific Inc., the global leader in serving science, has introduced the Gibco™ Efficient-Pro™ Medium (+) Insulin, a next-generation medium tailored to enhance titers and boost productivity in insulin-dependent CHO cell lines. This launch expands the company’s Efficient-Pro portfolio, providing biopharma manufacturers, biotech companies, and CDMOs with a solution that simplifies workflows while maintaining high product quality.

“With Efficient-Pro Medium (+) Insulin, we’re building on our commitment to remove barriers in bioproduction and help our customers achieve more. This latest innovation enables our customers to scale up rapidly, adapt to evolving project needs, and accelerate the delivery of life-changing therapies to patients. Efficient-Pro Medium (+) Insulin delivers on that promise by providing the tools and support needed to streamline processes, minimise risk and bring new treatments to market faster and more efficiently than ever before,” said Andy Campbell, senior director of research and development at Thermo Fisher Scientific. 

The new medium is engineered to address industry demands for higher yields, offering up to 61% greater protein titers compared to alternatives. It supports robust growth and high viable cell densities across a broad range of insulin-dependent CHO cell lines, while ensuring flexibility through multiple packaging configurations. With Thermo Fisher’s Advanced Granulation Technology™ (AGT™) dry media format, it further enables rapid reconstitution, scalability, and reduced handling complexity. Importantly, the formulation is animal origin–free (AOF), minimising process variability and regulatory challenges.

“Our announcement represents a significant enhancement in bioprocessing technology. By integrating our AGT format and ensuring an AOF formulation, we are addressing key industry challenges and providing our customers with a reliable, high-performance solution. Efficient-Pro Medium (+) Insulin underscores our dedication to innovation and our mission to support the development of groundbreaking therapies that improve patient outcomes worldwide,” said Sara Henneman, vice president and general manager of Thermo Fisher Scientific’s cell culture and cell therapy business. 

As biologics development accelerates and supply chain agility becomes more critical, Efficient-Pro Medium (+) Insulin provides a future-ready bioproduction solution. By eliminating manual insulin supplementation and supporting consistent, high-quality results, it helps streamline process development for monoclonal antibodies, bispecifics, Fc-fusion proteins, and other therapeutic proteins. This launch reflects Thermo Fisher’s commitment to empowering manufacturers with tools that optimise productivity while reducing cost and complexity in biologics manufacturing.